Health Costs

New and noteworthy

The MIDTERMS

“...the search for a single top issue through polling questions — whether it’s health costs, or gas prices, or the cost of food — is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, ‘cost of living.’” — Drew Altman, KFF Founding President and CEO

Are Health Care Costs THE Top Issue for Voters?

In a new column, Dr. Drew Altman, Founding President and CEO, analyzes the polling on health costs as a voting issue and concludes that there is no one top voting issue. He writes: “I have come to the conclusion that the search for a single top issue through polling questions—whether it’s health costs, or gas prices, or the cost of food—is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, “cost of living.”

Health System Tracker

Stay informed.

Stay informed.

Filter

1,391-1,400 of 1,609 results

  • Regulation of Private Long-Term Care Insurance: Implementation Experience and Key Issues

    Report

    Regulation of Private Long-Term Care Insurance: Implementation Experience and Key Issues While private long-term care insurance (LTCI) has been available since the mid-1970s, its popularity has grown rapidly in recent years, and Congress is considering proposals that would further encourage LTCI purchase through expanded tax subsidies. Yet there has been little research on how well LTCI works and how much security it really provides. This report focuses on consumer protections for individuals buying LTCI in…

  • Private Long-Term Care Insurance:  Who Should Buy It and What Should They Buy?

    Report

    Private Long-Term Care Insurance: Who Should Buy It and What Should They Buy? Despite the growing interest in private long-term care insurance (LTCI), there has been little independent examination of how much protection LTCI policies provide consumers or whether LTCI policies are a worthwhile purchase for people of average means. This report draws on data from the 1998 Survey of Consumer Finances (SCF) and the 1996 Medical Expenditures Panel Survey (MEPS) to explore the feasibility…

  • Paying for Choice: The Cost Implications of Health Plan Options For People on Medicare

    Report

    This report illustrates the financial stakes for Medicare beneficiaries when making choices about supplemental insurance coverage, by examining how much people on Medicare could spend out-of-pocket including premiums and other cost-sharing requirements under different supplemental insurance options. To assess the cost implications of choosing between different Medigap and Medicare+Choice insurance options, the research team estimated the range in health care expenditures associated with three prototypical beneficiaries (a 50 year-old man with disabilities, a relatively healthy…

  • A Guide to Developing Assistance Programs for Health Care Consumers

    Report

    The Health Rights Hotline, based in Sacramento, California, wasestablished in 1997 as a model to demonstrate and assess how anindependent assistance program can help consumers successfully accesscare, navigate the health care system, and improve the system for allhealth care consumers. Based on the experiences of the Health Rights Hotline, this Guideprovides a framework and specific steps that organizations may take to set up a consumer assistance program. Areas covered include program design, staffing and training,…

  • The Current State of Retiree Health Benefits: Findings from the Kaiser/Hewitt 2002 Retiree Health Survey

    Other Post

    The Current State of Retiree Health Benefits: Findings from the Kaiser/Hewitt 2002 Retiree Health Survey This report presents findings from a study of large private-sector employers conducted by researchers at Hewitt Associates and the Kaiser Family Foundation between July and September of 2002. The study is based on survey responses of 435 large private-sector firms (1,000+ employees) that currently offer retiree health benefits, and includes 36% of all Fortune 100 companies and 28% of all…

  • Comparisons of the Liability Provisions of the House and Senate Patients’ Rights Bills

    Report

    A hotly debated issue in Congress has been the issue of when health maintenance organizations, health insurers, and those who administer health benefit plans should be financially liable to their plan participants for a denial of a claim or for damages for any injuries that result from such denials (known as health plan liability ). This new report by Gary Claxton of the Georgetown Institute for Health Care Research and Policy describes the health plan…

  • Medicare+Choice in California: Lessons and Insights

    Report

    Thirty-five percent of all California Medicare beneficiaries are enrolled in a M+C plan, far in excess of the 14 percent rate nationwide. This report seeks to identify what lessons for the nation can be drawn from the California M+C experience, as Congress debates the implications of major withdrawals from the M+C program and potential policy changes aimed at reversing this trend. The report is based largely on analysis of M+C data on plan participation, withdrawals,…

  • Latest Findings on Employer-Based Coverage of Contraception

    Other Post

    This memorandum provides background on the issue of contraceptive coverage and presents new findings from the soon to be released Kaiser/HRET 2002 Annual Survey of Employer-Sponsored Health Benefits. Employer Based Coverage of Contraception

  • Federal Policies Affecting The Cost and Availability of New Pharmaceuticals

    Report

    This report by Michael Gluck of the Georgetown University Institute for Health Care Research and Policy examines several ways in which the federal government influences the availability and cost of prescription drugs, including 1) intellectual property protection the laws and policies which regulate and influence patents and generic competition (include the Hatch-Waxman Act), 2) federal support for drug research and development, 3) federal tax subsidies through various tax credits available to pharmaceutical firms, and 4)…